Alzheimer's Disease and Related Disorders (MERE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01315704 |
Recruitment Status
: Unknown
Verified March 2011 by University Hospital, Angers.
Recruitment status was: Recruiting
First Posted
: March 15, 2011
Last Update Posted
: March 15, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Alzheimer's Disease Gait Apraxia Impaired Cognition | Drug: Drug intervention |
Although gait disorders are frequently associated with Alzheimer's disease and related disorders (ADRD), few studies have focused on cognitive motor effects of anti-dementia drugs and vitamin D.
The objectives of this study are to
- Compare characteristics of gait and balance measured among patients with ADRD separated into 3 groups according to stages of disease (i.e., pre-dementia, mild and moderate dementia stages)
- To determine the effects of anti-dementia drugs and vitamin D on cognitive motor abnormalities
- To determine whether motor abnormalities could be associated with cognitive impairments, specifically executive dysfunctions
- To establish a database at Angers University Memory Center.
Study Type : | Observational |
Estimated Enrollment : | 700 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Maladie d'Alzheimer et Maladies apparentées : Caractérisation Des Anomalies Cognitivo-motrices, et Des Effets Des médicaments Anti-démence et de la Vitamine D à Partir de la Mise en Place d'Une Base de données au CMRR du CHU d'Angers |
Study Start Date : | November 2009 |
Estimated Primary Completion Date : | November 2017 |
Estimated Study Completion Date : | November 2017 |

Group/Cohort | Intervention/treatment |
---|---|
Group 1
Patients with Mild Cognitive Impairment
|
Drug: Drug intervention
before-after interventional (anti-dementia drugs and/or vitamin D) study
Other Name: Anti-dementia drugs and/or vitamin D
|
Group 2
Patients with Mild Alzheimer's disease or related disorders
|
Drug: Drug intervention
before-after interventional (anti-dementia drugs and/or vitamin D) study
Other Name: Anti-dementia drugs and/or vitamin D
|
Group 3
Patients with Moderate Alzheimer's disease or related disorders
|
Drug: Drug intervention
before-after interventional (anti-dementia drugs and/or vitamin D) study
Other Name: Anti-dementia drugs and/or vitamin D
|
- Spatiotemporal gait parameters [ Time Frame: baseline ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- All elderly patients from the University Memory Center of Angers University Hospital.
- Able to walk without any walking aid on 15 meters
- Mini-Mental Status Examination score > 10
- Being affiliated to a social security regime
Exclusion Criteria:
- Mini-Mental Status Examination score ≤ 10
- Subject suffering from pre-existing impellent disturbances
- History of cerebrovascular accident or other cerebro-spinal pathology
- Poor workmanship of the written or oral French language
- Use of walking aid such as walking frame with wheels or tricycle.
- Acute medical or surgical disease in the past 3 months
- Refusal to participate (or trustworthy person)
- Near visual acuity < 2/10

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315704
Contact: Cedric ANNWEILER, DM | (+33) 241354725 | ceannweiler@chu-angers.fr |
France | |
Cédric ANNWEILER , MD | Recruiting |
Angers, France, 49933 | |
Contact: Cedric ANNWEILER, MD (+33)241354725 ceannweiler@chu-angers.fr |
Principal Investigator: | Cedric ANNWEILER, MD | Memory Centre of Angers University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Cédric ANNWEILER ; MD, Memory Centre of Angers University Hospital |
ClinicalTrials.gov Identifier: | NCT01315704 History of Changes |
Other Study ID Numbers: |
2009-15 |
First Posted: | March 15, 2011 Key Record Dates |
Last Update Posted: | March 15, 2011 |
Last Verified: | March 2011 |
Additional relevant MeSH terms:
Apraxias Gait Apraxia Alzheimer Disease Cognitive Dysfunction Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Psychomotor Disorders |
Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms Cognition Disorders Gait Disorders, Neurologic Vitamins Vitamin D Ergocalciferols Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents |